An interventional study of HPV detection in anal canal samples in HPV Infection, sponsored by Centre Hospitalier Universitaire de Besancon. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-11.
Sponsored by Centre Hospitalier Universitaire de Besancon · Not applicable, Interventional, and Prevention
Human papillomavirus (HPV) are involved in up to 95 % of anal canal neoplastic lesions. Little is known about HPV carriage in anal canal previous to cancer occurrence in the population and pre-neoplastic lesions, and their risk factors. PAPILLAN is a prospective study that aims to study HPV infection (HPV low grade and high grade genotypes) prevalence in anal canal in a population non selected by its HIV status. In that purpose patients are prospectively recruited in a french university hospital gastroenterology unit and anal smears are collected during a colonoscopy with cytobrush.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 500 is above the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →Centre Hospitalier Universitaire de Besancon is the lead sponsor of 439 studies on the registry; 97 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Procedure: HPV detection in anal canal samples
Additional anal taking during the colonoscopy with cytobrush
anal canal HPV infection
Time frame: at inclusion (the day of colonoscopy)
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Besancon